Media Articles Related to Edluar (Zolpidem)
Neurofeedback treatment for insomnia no better than placebo
Source: Sleep / Sleep Disorders / Insomnia News From Medical News Today [2017.02.25]
Neurofeedback has been considered a potential insomnia therapy for decades. However, breaking research finds it to be no more effective than a placebo.
New guideline provides clinical recommendations for specific insomnia drugs
Source: Sleep / Sleep Disorders / Insomnia News From Medical News Today [2017.02.16]
DA new clinical practice guideline is the first from the American Academy of Sleep Medicine to provide comprehensive, evidence-based analyses of individual agents commonly used in the treatment of...
Insomnia increases asthma risk in adults
Source: Sleep / Sleep Disorders / Insomnia News From Medical News Today [2017.02.02]
A new study suggests people who experience insomnia symptoms are at a higher risk of developing asthma in adulthood compared with insomnia-free adults.
Sleep Disorders: Insomnia, Sleep Apnea, and More
Source: MedicineNet modafinil Specialty [2016.08.22]
Title: Sleep Disorders: Insomnia, Sleep Apnea, and More
Created: 7/23/2010 2:39:00 PM
Last Editorial Review: 8/22/2016 12:00:00 AM
Sleep Better, Conquer Insomnia
Source: MedicineNet zolpidem Specialty [2016.06.24]
Title: Sleep Better, Conquer Insomnia
Created: 12/10/2008 12:00:00 AM
Last Editorial Review: 6/24/2016 12:00:00 AM
Published Studies Related to Edluar (Zolpidem)
Efficacy and safety of a polyherbal sedative-hypnotic formulation NSF-3 in
primary insomnia in comparison to zolpidem: a randomized controlled trial. 
insomnia... CONCLUSIONS: NSF-3 is a safe and effective short-term alternative to zolpidem for
Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset
following spontaneous middle-of-the-night awakening in insomnia in a randomized,
double-blind, placebo-controlled, outpatient study. 
to sleep after MOTN awakenings... CONCLUSIONS: 3.5 mg ZST used as needed significantly reduced latency to return to
Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. [2011.07]
CONCLUSIONS: Zolpidem extended-release administered concomitantly with escitalopram for up to 24 weeks was well tolerated and improved insomnia and some sleep-related next-day symptoms and next-day functioning in patients with MDD but did not significantly augment the antidepressant response of escitalopram. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00296179. (c) Copyright 2011 Physicians Postgraduate Press, Inc.
The use of a non-benzodiazepine hypnotic sleep-aid (Zolpidem) in patients undergoing ACL reconstruction: a randomized controlled clinical trial. [2011.05]
PURPOSE: Previous studies have addressed post-operative pain management after ACL reconstruction by examining the use of intra-articular analgesia and/or modification of anesthesia techniques. To our knowledge, however, no previous studies have evaluated the effect of zolpidem on post-operative narcotic requirements, pain, and fatigue in patients undergoing outpatient arthroscopic ACL reconstruction. The purpose of this prospective, blinded, randomized, controlled clinical study was to evaluate the effect of zolpidem on post-operative narcotic requirements, pain, and fatigue in patients undergoing outpatient arthroscopic ACL reconstruction... CONCLUSION: Adding zolpidem to the post-operative medication regimen after arthroscopic ACL reconstruction helps to lower the amount of narcotic pain medication required for adequate analgesia. LEVEL OF EVIDENCE: Randomized controlled clinical trial, Level I.
Zolpidem and zopiclone impair similarly monotonous driving performance after a single nighttime intake in aged subjects. [2011.04]
RATIONALE: Although hypnotics are primarily used by older people, the residual effects the morning after a single nighttime intake of the two most commonly prescribed hypnotics, zolpidem (Zp) and zopiclone (Zc), on older middle-aged drivers have not been evaluated and compared... CONCLUSIONS: This is the first study revealing residual effects of Zp on driving performance in ageing drivers which are similar to that of Zc. Studying the effects of medication in different age ranges appears useful to complete the studies on behavioural-pharmacological effects of medication. To reduce the incidence of driving accidents due to prescription drugs, patients should be warned at the time of treatment initiation that they should avoid driving.